Navigation Links
The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
Date:5/8/2013

Dallas, TX (PRWEB) May 08, 2013

The National Plaintiff’s Law Firm of Baron and Budd is now handling lawsuits pertaining to the recall of Granuflo, the brand name of a dialysate (http://www.fda.gov/medicaldevices/safety/listofrecalls/ucm309990.htm
). Dialysate is used when a patient undergoes dialysis, a long-term medical treatment used to treat kidney conditions. Granuflo has been known to allegedly cause various health issues including heart attack and stroke. The Granuflo lawyers at Baron and Budd are currently working to aid patients and families that have allegedly endured significant health issues after using Granuflo (IN RE: FRESENIUS GRANUFLO/NATURALYTE. DIALYSATE PRODUCTS LIABILITY LITIGATION. MDL No. 2428, Dist. Of Mass).

“It is Baron and Budd’s mission to uncover the facts that manufacturers don’t want their customers to know,” said Russell Budd, co-founder and managing shareholder of Baron and Budd. "When important research uncovers dangerous side effects, that research should immediately be made public."

According a New York Times article dated June 15, 2012, Fresenius Medical Care is the manufacturer of Granuflo and the world’s largest producer of products and services for kidney dialysis. More than one-third of the over 400,000 Americans who undergo dialysis treatments go to Fresenius clinics each year. (http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=0)

The New York Times also reported that the Federal Drug Administration (FDA) issued a Granuflo a recall on March 29, 2012 to change the drug’s prescribing instructions. The recall said that the use of Granuflo could potentially lead to significant heart problems in patients, such as low blood pressure and cardiac arrhythmia. However, Fresenius allegedly knew that the product could harm patients as early as November 2011, according to an internal company memo. (http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=1&;)

If you or someone you know has undergone dialysis with Granuflo treatments and experienced severe health complications, contact Baron and Budd’s Granuflo lawyers today at 1.866.855.4556 or email us at info (at) baronbudd (dot) com.

For more information about our Granuflo attorneys, visit Baron and Budd’s website here: http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/.

For more than 35 years, Baron and Budd lawyers have been protecting the rights of people against negligent companies. The firm has an established track record of success when going up against large corporations, including pharmaceutical companies. Recently, our lawyers were involved in the litigation surrounding diabetes drug Avandia. Baron and Budd represented more than 7,000 patients allegedly harmed by Avandia use, and currently represents numerous states in lawsuits against manufacturer GlaxoSmithKline (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, E.D. Pa.). In the 1990s, the firm was closely involved in the litigation surrounding then-popular diet drug Fen-Phen. The resulting settlement was valued at over $1.275 billion (In re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, Case No. 98- MDL No. 1203 (E.D. Pa.).

About Baron & Budd

The law firm of Baron & Budd, with offices in Dallas, Baton Rouge, Austin and Los Angeles, is a nationally recognized law firm with over 35 years of “Protecting What’s Right” for people, communities and businesses harmed by negligence. Baron & Budd’s size and resources enable the firm to take on large and complex cases. The firm represents individuals, governmental and business entities in areas as diverse as water contamination, Gulf oil spill, Qui Tam, California Proposition 65 violations, unsafe drugs and medical devices, Chinese drywall, deceptive advertising, consumer financial fraud, securities fraud and asbestos cancers such as mesothelioma.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10700127.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Transitions of Care Coalition to Host Regional Summit in Nashville
2. ZTL Linear LED Tube To Illuminate LIGHTFAIR® International 2013
3. National Quality Forum Testifies at U.S. House Ways and Means Health Subcommittee Hearing
4. Hub International to Offer Webinar on Preparing for Health Care Reform in 2014
5. New Video from the International Essential Tremor Foundation Addresses the Emotional and Psychosocial Aspects of Essential Tremor
6. Penn study shows national movement against non-medically indicated deliveries prior to 39 weeks
7. Grief and Mother’s Day: National Grief Expert's 10 Tips to Remember Mom with Peace
8. Nurse.com Releases New E-Book of Inspirational Stories in Honor of National Nurses Week 2013
9. Kamut International Announces Partnership with Professional Ironman Champion Linsey Corbin
10. Newport Board Group, a National Business Advisory Firm of CEOs Serving the Emerging Middle Market, Releases a Technology Roadmap for Private Companies
11. Contemporary Forums Celebrates National Nurses Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... Aliso Viejo, California (PRWEB) , ... January 15, 2017 , ... ... create a stylistic slideshow with complete customization and ease," said Christina Austin - CEO ... variety of controls so that users can edit the style and animation of their ...
(Date:1/15/2017)... ... January 15, 2017 , ... The JPR ... pleased to announce that it will be assisting HackensackUMC Mountainside with its public ... Ridge townships, servicing all surrounding towns. The firm will be working closely with ...
(Date:1/14/2017)... ... ... Volume 3 is a self animating masking transition which allows users to reveal any object ... Austin - CEO of Pixel Film Studios. , TransFreeze Volume 3 provides FCPX ... the next. , To use “Cut-Out First” presets, choose a video clip and ...
(Date:1/13/2017)... , ... January 13, 2017 , ... KOAMTAC ®, ... will be showcasing the next generation companion scanner and data collector at the National ... KDC270 has been created as an answer to the market’s need for more compact ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about as ... brush their teeth. Sadly, most dental hygiene products in the market contain chemical ingredients ... these people, continuing their daily oral care routine to keep their teeth white and ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... , January 13, 2017 Constant research ... AIDS will collectively contribute to the demand for western blotting ... a value of US$ 551.0 Mn by 2016 end. Developing ... the most lucrative markets for western blotting, whereas ... globally. ...
(Date:1/13/2017)... YORK , January 13, 2017 ... equities to see how they have fared at yesterday,s ... ), Galena Biopharma Inc. (NASDAQ: GALE ), ... These companies harness cellular and biomolecular processes to develop ... reduce our environmental footprint, feed the hungry, use less ...
Breaking Medicine Technology: